229 related articles for article (PubMed ID: 26916619)
21. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
22. Conditional disruption of Axin1 leads to development of liver tumors in mice.
Feng GJ; Cotta W; Wei XQ; Poetz O; Evans R; Jardé T; Reed K; Meniel V; Williams GT; Clarke AR; Dale TC
Gastroenterology; 2012 Dec; 143(6):1650-9. PubMed ID: 22960659
[TBL] [Abstract][Full Text] [Related]
23. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
24. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
25. c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
[TBL] [Abstract][Full Text] [Related]
26. RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes.
Recouvreux MS; Grasso EN; Echeverria PC; Rocha-Viegas L; Castilla LH; Schere-Levy C; Tocci JM; Kordon EC; Rubinstein N
Oncotarget; 2016 Feb; 7(6):6552-65. PubMed ID: 26735887
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression.
Zhang X; Farrell AS; Daniel CJ; Arnold H; Scanlan C; Laraway BJ; Janghorban M; Lum L; Chen D; Troxell M; Sears R
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2790-5. PubMed ID: 21808024
[TBL] [Abstract][Full Text] [Related]
28. Epigenomics-based identification of oestrogen-regulated long noncoding RNAs in ER+ breast cancer.
Zhang Z; Yu W; Tang D; Zhou Y; Bi M; Wang H; Zheng Y; Chen M; Li L; Xu X; Zhang W; Tao H; Jin VX; Liu Z; Chen L
RNA Biol; 2020 Nov; 17(11):1590-1602. PubMed ID: 32506995
[TBL] [Abstract][Full Text] [Related]
29. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
30. Thr160 of Axin1 is critical for the formation and function of the β-catenin destruction complex.
Koyama-Nasu R; Hayashi T; Nasu-Nishimura Y; Akiyama T; Yamanaka R
Biochem Biophys Res Commun; 2015 Apr; 459(3):411-5. PubMed ID: 25735981
[TBL] [Abstract][Full Text] [Related]
31. Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells.
Liu J; Li J; Sidell N
Cancer Chemother Pharmacol; 2007 Feb; 59(2):217-25. PubMed ID: 16738884
[TBL] [Abstract][Full Text] [Related]
32. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma.
Wang Y; Liu S; Zhu H; Zhang W; Zhang G; Zhou X; Zhou C; Quan L; Bai J; Xue L; Lu N; Xu N
Int J Cancer; 2008 Aug; 123(3):561-8. PubMed ID: 18498136
[TBL] [Abstract][Full Text] [Related]
33. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
34. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
35. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
36. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
37. Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor.
Hong D; Fritz AJ; Finstad KH; Fitzgerald MP; Weinheimer A; Viens AL; Ramsey J; Stein JL; Lian JB; Stein GS
Mol Cancer Res; 2018 Dec; 16(12):1952-1964. PubMed ID: 30082484
[TBL] [Abstract][Full Text] [Related]
38. Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.
Haynes BP; Viale G; Galimberti V; Rotmensz N; Gibelli B; Smith IE; Dowsett M
Breast Cancer Res Treat; 2014 Nov; 148(2):327-35. PubMed ID: 25367875
[TBL] [Abstract][Full Text] [Related]
39. TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation.
Hou Y; Ding M; Wang C; Yang X; Ye T; Yu H
Exp Cell Res; 2020 Feb; 387(2):111750. PubMed ID: 31786079
[TBL] [Abstract][Full Text] [Related]
40. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
Butt AJ; McNeil CM; Musgrove EA; Sutherland RL
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S47-59. PubMed ID: 16113099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
